EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

HER2 overexpression in urothelial carcinoma with GATA3 and PPARG copy number gains

Xiaolin Zhu iD, Emily Chan, Michelle L Turski, Carlos Espinosa Mendez, Sarah C Hsu, Vipul Kumar, Chase Shipp, Tanya Jindal, Kevin Chang, Courtney Onodera, W Patrick Devine, James P Grenert und 10 weitere

The Oncologist · 05.08.2024 · 29 (8) · e1094-e1097

DOI: 10.1093/oncolo/oyae127 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, online erschienen am 22.06.2024. Verfasst von Xiaolin Zhu und 21 weiteren Autor:innen. Beteiligte Einrichtung: Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, United States. Hauptthemen laut MEDLINE: DNA Copy Number Variations, GATA3 Transcription Factor, PPAR gamma, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

HER2, encoded by the ERBB2 gene, is an important druggable driver of human cancer gaining increasing importance as a therapeutic target in urothelial carcinoma (UC). The genomic underpinnings of HER2 overexpression in ERBB2 nonamplified UC are poorly defined. To address this knowledge gap, we investigated 172 UC tumors from patients treated at the University of California San Francisco, using immunohistochemistry and next-generation sequencing. We found that GATA3 and PPARG copy number gains individually predicted HER2 protein expression independently of ERBB2 amplification. To validate these findings, we interrogated the Memorial Sloan Kettering/The Cancer Genome Atlas (MSK/TCGA) dataset and found that GATA3 and PPARG copy number gains individually predicted ERBB2 mRNA expression independently of ERBB2 amplification. Our findings reveal a potential link between the luminal marker HER2 and the key transcription factors GATA3 and PPARG in UC and highlight the utility of examining GATA3 and PPARG copy number states to identify UC tumors that overexpress HER2 in the absence of ERBB2 amplification. In summary, we found that an increase in copy number of GATA3 and PPARG was independently associated with higher ERBB2 expression in patient samples of UC. This finding provides a potential explanation for HER2 overexpression in UC tumors without ERBB2 amplification and a way to identify these tumors for HER2-targeted therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DNA Copy Number VariationsGATA3 Transcription FactorPPAR gammaErb-b2 Receptor Tyrosine KinasesAgedFemaleHumansMaleMiddle AgedBiomarkers, TumorGene AmplificationGene Expression Regulation, NeoplasticUrinary Bladder NeoplasmsUrologic Neoplasms

Stichwörter der Autor:innen

ERBB2 amplificationGATA3PPARGHER2urothelial cancer

Substanzen

Biomarkers, TumorGATA3 Transcription FactorPPAR gammaErb-b2 Receptor Tyrosine KinasesERBB2 protein, humanGATA3 protein, humanPPARG protein, human

Autor:innen und Institutionen

  • Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, United States.
  • Department of Medicine, University of California San Francisco, San Francisco, CA, United States.
  • Department of Pathology, Stanford Medical Center, Stanford, CA, United States.
  • School of Medicine, University of California San Francisco, San Francisco, CA, United States.
  • Department of Pathology, University of California San Francisco, San Francisco, CA, United States.
  • Department of Urology, University of California San Francisco, San Francisco, CA, United States.

ORCID-Profile: Xiaolin Zhu, Vadim S Koshkin

Förderung

  • NCI NIH HHS

Zitieren

APA

Zhu, X., Chan, E., Turski, M. L., Mendez, C. E., Hsu, S. C., Kumar, V., Shipp, C., Jindal, T., Chang, K., Onodera, C., Devine, W. P., Grenert, J. P., Stohr, B. A., Ding, C. C., Stachler, M. D., Quigley, D. A., Feng, F. Y., Chu, C. E., Porten, S. P., …, & Koshkin, V. S. (2024). HER2 overexpression in urothelial carcinoma with GATA3 and PPARG copy number gains. The Oncologist, 29(8), e1094-e1097. https://doi.org/10.1093/oncolo/oyae127

Vancouver

Zhu X, Chan E, Turski ML, Mendez CE, Hsu SC, Kumar V, et al. HER2 overexpression in urothelial carcinoma with GATA3 and PPARG copy number gains. The Oncologist. 2024;29(8):e1094-e1097. doi:10.1093/oncolo/oyae127

BibTeX
@article{Zhu2024,
  author = {Zhu, Xiaolin and Chan, Emily and Turski, Michelle L and Mendez, Carlos Espinosa and Hsu, Sarah C and Kumar, Vipul and Shipp, Chase and Jindal, Tanya and Chang, Kevin and Onodera, Courtney and Devine, W Patrick and Grenert, James P and Stohr, Bradley A and Ding, Chien-Kuang Cornelia and Stachler, Matthew D and Quigley, David A and Feng, Felix Y and Chu, Carissa E and Porten, Sima P and Chou, Jonathan and Friedlander, Terence W and Koshkin, Vadim S},
  title = {HER2 overexpression in urothelial carcinoma with GATA3 and PPARG copy number gains},
  journal = {The Oncologist},
  year = {2024},
  volume = {29},
  number = {8},
  pages = {e1094--e1097},
  doi = {10.1093/oncolo/oyae127}
}
Kostenlos starten →